drugset / Trial / NCT01302249

AR-12286 in Combination With Latanoprost

NCT01302249

Phase 2 Completed 66 enrolled Aerie Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).

Timeline

Start
2011-02
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Timolol Other / unclassified 0.5 %
Subject VEROSUDIL Small molecule 0.5 %
Background Latanoprost Small molecule 0.005 %